Precision medicine aims to tailor cancer therapies to target specific tumorpromoting aberrations. For tumors that lack actionable drivers, extensive molecular characterization and pre-clinical drug efficacy studies will be required to match patients with the appropriate targeted therapy. A cell line maintained at low passage and a patient-derived xenograft model (PDX) were generated using a fresh biopsy from a patient with a poorly-differentiated neuroendocrine tumor of unknown primary origin. Next-generation sequencing, high throughput signaling network analysis, and drug efficacy trials were then conducted to identify actionable targets for therapeutic intervention. No actionable mutations were identified after whole exome sequencing of the patient's DNA; however, whole genome sequencing revealed amplification of the 3q and 5p chromosomal arms, that include the PIK3CA and RICTOR genes, respectively. Consistent with amplification of these genes, pathway analysis revealed activation of the AKT pathway.
Introduction
The application of precision medicine into clinical practice has revolutionized the management of cancer over the last decade. Next-generation sequencing (NGS) technologies allow the identification of actionable mutations in tumors, to which targeted therapies can be developed with the potential to improve therapeutic index regarding impact on tumor versus normal tissues in contrast to conventional cytotoxics. Increasingly, NGS of patient tumor samples guides patient stratification into clinical trials, such that only the patients bearing specific molecular alterations will receive the corresponding targeted therapy.
The TARGET (Tumour chARacterisation to Guide Experimental
Targeted Therapy) protocol aims to stratify patients based on genetic alterations identified in tumor specimens and/or circulating-free DNA. In addition, in vivo drug efficacy studies in patient-derived xenografts (PDX) are performed for a subset of patients. This approach matches patients to the most appropriate and available early phase clinical trials according to their molecular alterations to maximize the chance of patient benefit from targeted therapies 1 .
Here we describe a case study (TAR007) of a patient with no smoking history and a poorly differentiated neuroendocrine tumor of unknown primary origin. These are rare tumors, characterized by poor prognosis, and these propensity to respond to treatment with AKT inhibitors.
Results
A patient presented with a poorly differentiated neuroendocrine tumor of unknown primary origin, and the tumor was surgically resected from the right axilla. An experimental pre-clinical study was designed to identify potentially druggable genetic alterations ( Figure 1A ). Tumor samples were inoculated into NSG mice to generate a PDX mouse model for use in drug efficacy studies. In parallel, tumor fragments were frozen for DNA sequencing and a low passage cell culture was derived after digestion of the tumor specimen.
WES of the tumor specimen was conducted to identify targetable alterations in this patient's tumor, and DNA from white blood cells was used as a control to exclude germline variants from the analysis. WES did not reveal any actionable mutations (Supplemental file 1). WGS was then 6 performed to identify copy number alterations. WGS analysis from both the tumor specimen and a PDX-derived sample revealed chromosome deletions at 3p and 14q, and amplifications in 3q, 5p, 13q and 17q ( Figure 1B ). Among the regions of amplification, we detected copy number gains of the PIK3CA (in 3q, 4 copies) and RICTOR (in 5p, 5 copies) genes, which are upstream activators of the oncogenic kinase AKT.
Fresh tumor biopsy-derived low passage cell cultures were then used to assess pathways activated in the tumor sample. Normal, non-transformed, primary cells were used as controls (NHBE and SAEC; Figure 1C ). Several components of the AKT pathway were specifically activated in the tumor- inhibition. Patients with RICTOR amplification might also benefit from mTOR inhibitors 6 ; however, these compounds were not tested since secondary resistance normally appears and involves reactivation of the PI3K-AKT or the MAPK pathways 7, 8 . Similar responses to AKT and PI3K inhibitors were observed in our PDX models, indicating that low passage cell cultures, when possible to generate, can be a powerful tool for initial inhibitor testing and aid in refining in vivo experiments. In addition, our data suggest that PIK3CA and RICTOR gene co-amplification may define a unique subset of patients with neuroendocrine tumors that will respond to AKT inhibitors, and could thus be used as an additional biomarker for treatment stratification. 
Phospho-arrays
The Proteome Profiler Human Phospho-Kinase and Human PhosphoReceptor Tyrosine Kinase (RTK) Array kits (R&D Systems) were used according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was done with GraphPad Prism, the Mann-Whitney test was used to assess differences between treatments; when P-value < 0.05, differences were considered significant.
Additional methods are described in the supplemental material.
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